Literature DB >> 15158123

Transient glucose deprivation causes upregulation of heme oxygenase-1 and cyclooxygenase-2 expression in cardiac fibroblasts.

Kenji Takeda1, Jie Lin, Shinji Okubo, Sumiyo Akazawa-Kudoh, Koji Kajinami, Seiyu Kanemitsu, Hiroichi Tsugawa, Tsugiyasu Kanda, Shinobu Matsui, Noboru Takekoshi.   

Abstract

Transient glucose deprivation (TGD) has been shown to induce a resistance to a subsequent ischemia and reperfusion injury in the heart. Induction of cyclooxygenase-2 (COX-2) and heme oxygenase-1 (HO-1) is known to mediate the powerful defensive adaptation of the heart against oxidative stress. In this study, we found that a 30-min incubation in the absence of glucose resulted in a rapid increased expression of COX-2 and HO-1 in cardiac fibroblasts as examined by real-time quantitative polymerase chain reaction (PCR) and western blot analysis. Interestingly, TGD increased the generation of reactive oxygen species (ROS) and caused the transient phosphorylation of p38 mitogen-activated protein kinase (MAPK) as well as the translocation of protein kinase C (PKC)- from the cytosolic to the membrane fraction. However, no significant change in the distribution of PKC-delta isoform was observed compared with the control. Pretreatment of the cells with an antioxidant, N-acetylcysteine (NAC), resulted in the inhibition of p38 MAPK phosphorylation and PKC- translocation during TGD. In addition, the induction of COX-2 and HO-1 expression by TGD was prevented by pretreatment with NAC or SB203580, a p38 MAPK inhibitor. Surprisingly, pretreatment with chelerythrine, an inhibitor of PKC, strongly augmented the HO-1 mRNA expression but blocked the COX-2 mRNA induction by TGD. These results demonstrate that briefly removing glucose from cultured cardiac fibroblasts induces COX-2 and HO-1 expression via generation of ROS and p38 MAPK phosphorylation, while the translocation of PKC- to the membrane fraction may participate in the induction of COX-2 but not in the HO-1 expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158123     DOI: 10.1016/j.yjmcc.2004.03.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Ischemic preconditioning via epsilon protein kinase C activation requires cyclooxygenase-2 activation in vitro.

Authors:  E Kim; A P Raval; R A Defazio; M A Perez-Pinzon
Journal:  Neuroscience       Date:  2007-02-20       Impact factor: 3.590

2.  Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent.

Authors:  Luyun Zou; Xiaoyuan Zhu-Mauldin; Richard B Marchase; Andrew J Paterson; Jian Liu; Qinglin Yang; John C Chatham
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

Review 3.  Heme oxygenase: the key to renal function regulation.

Authors:  Nader G Abraham; Jian Cao; David Sacerdoti; Xiaoying Li; George Drummond
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-01

4.  CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms.

Authors:  Seong-Su Han; Liangping Peng; Seung-Tae Chung; Wendy DuBois; Sung-Ho Maeng; Arthur L Shaffer; Michael B Sporn; Siegfried Janz
Journal:  Mol Cancer       Date:  2006-06-07       Impact factor: 27.401

5.  Regulation of autophagy by glucose in Mammalian cells.

Authors:  Félix Moruno; Eva Pérez-Jiménez; Erwin Knecht
Journal:  Cells       Date:  2012-07-27       Impact factor: 6.600

6.  Transcriptome responses to heat stress in hypothalamus of a meat-type chicken.

Authors:  Hongyan Sun; Runshen Jiang; Shengyou Xu; Zebin Zhang; Guiyun Xu; Jiangxia Zheng; Lujiang Qu
Journal:  J Anim Sci Biotechnol       Date:  2015-02-17

7.  Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer.

Authors:  Hyun Joo Jang; Eun Mi Hong; Mikang Kim; Jae Hyun Kim; Juah Jang; Se Woo Park; Hyun Wu Byun; Dong Hee Koh; Min Ho Choi; Sea Hyub Kae; Jin Lee
Journal:  Oncotarget       Date:  2016-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.